Erlotinib/Tarceva can be taken for up to several years

Erlotinib (Erlotinib) usually recommends "continuous medication", that is, no clear treatment limit is set on the premise that the disease is under control. If the patient responds well to the drug, the tumor stabilizes or shrinks, and the side effects are tolerable, erlotinib can be taken continuously for many years. There are reports that some patients with non-small cell lung cancer and pancreatic cancer have achieved long-term control of their diseases after using erlotinib, and it is not uncommon for them to take the drug continuously for more than three or even five years. This long-term management idea is different from traditional chemotherapy "cyclical" administration, but emphasizes stability and maintenance.

However, as treatment time increases, drug resistance often emerges gradually. This is a common challenge for EGFR-targeted drugs. After using erlotinib for months or years, new mutations, such as T790M, may develop in some patients, thereby weakening the drug's efficacy. Once resistance occurs, patients may need to switch to a new generation of EGFR inhibitors or combine them with other treatments. Therefore, although erlotinib can theoretically be used for a long time, the actual period of medication still needs to be evaluated based on the dynamics of the disease.

From a tolerability perspective, side effects such as rash, diarrhea, or changes in liver function that occur in most patients during long-term use are usually controllable and do not limit the long-term application of the drug. Through dosage adjustment and symptomatic treatment, most patients can persist, which is one of the reasons why they can continue to take it for many years.

Generally speaking, erlotinib does not have a fixed maximum period of medication, but the duration of medication is determined based on the patient's condition. In appropriate populations, it can be used as a long-term management tool for several years to maintain disease control and quality of life. With the deepening of research on precision medicine and resistance mechanisms, there will be more personalized strategies to optimize the service life and therapeutic effect of erlotinib in the future.

Reference materials:https://en.wikipedia.org/wiki/Erlotinib